Samsung Biologics, Kurma Partners enter strategic partnership for development & manufacturing of biologics for Kurma’s portfolio companies

Samsung Biologics, a global contract development and manufacturing organization (CDMO) and Kurma Partners, a European venture capital firm in healthcare and biotechnology, announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.

Under the terms of the multi year agreement, Samsung Biologics will provide customizable chemistry, manufacturing, and control (CMC) development services for Kurma Partners’ portfolio companies to streamline the gene to Investigational New Drug ( IND process , de risk uncertainties in CMC, and accelerate the lead candidate selection through entry into first in human studies with seamless transitions along further clinical development The portfolio companies will be able to leverage Samsung Biologics’ state of the art facilities, proprietary technology platforms, and CMC related expertise.

“As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies,” said John Rim, president and CEO of Samsung Biologics. “With our in depth knowledge on effective scale up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”

“We are very excited to partner with Samsung Biologics, a world leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologic s from discovery to the market. market.” said Daniel Parera, M.D., Partner at Kurma Partners.

The latest agreement reflects Samsung Biologics’ continued commitment to support emerging biotech companies on their drug development and manufacturing journey as well as further increase its business presence in major sectors with a focus on the US and European markets.

Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture.

Founded in July 2009 and based in Paris and Munich, Kurma Partners is a key European Venture Capital firm in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth capital, in particular through its funds Kurma Biofund I, II, III, Kurma Diagnostics and Kurma Diagnostics 2 and its recent Kurma Growth Opportunities Fund as well based on its networks the company has built with prestigious research and academic institutes, premier cluster organisations and hospitals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!